Flurbiprofen
- Generic Name
- Flurbiprofen
- Drug Type
- Small Molecule
- Chemical Formula
- C15H13FO2
- CAS Number
- 5104-49-4
- Unique Ingredient Identifier
- 5GRO578KLP
- Background
Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen.
- Indication
Flurbiprofen tablets are indicated for the acute or long-term symptomatic treatment of rheumatoid arthritis, osteorarthritis and anklosing spondylitis. It may also be used to treat pain associated with dysmenorrhea and mild to moderate pain accompanied by inflammation (e.g. bursitis, tendonitis, soft tissue trauma). Topical ophthalmic formulations may be used pre-operatively to prevent intraoperative miosis.
- Associated Conditions
- Ankylosing Spondylitis (AS), Back Pain, Acute, Chronic Back Pain, Menstrual Distress (Dysmenorrhea), Muscle Spasms, Non-Articular Rheumatic Muscle Spasms, Osteoarthritis (OA), Pain, Pain, Inflammatory, Post Traumatic Pain, Postoperative pain, Rheumatoid Arthritis, Spinal pain
Combination of Remifentanil and Flurbiprofen in Sedation and Analgesia for ESWL of Pancreatic Stone
- Conditions
- Pancreatic Stone Disease
- Interventions
- First Posted Date
- 2013-11-28
- Last Posted Date
- 2015-02-04
- Lead Sponsor
- Changhai Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT01998217
- Locations
- 🇨🇳
Department of Anesthesiology, Changhai Hospital, Shanghai, Shanghai, China
Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method
- First Posted Date
- 2013-11-18
- Last Posted Date
- 2017-09-28
- Lead Sponsor
- Reckitt Benckiser LLC
- Target Recruit Count
- 122
- Registration Number
- NCT01986361
- Locations
- 🇺🇸
University of Connecticut - Student Health Services, Storrs, Connecticut, United States
Bioequivalence Study of FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET in Healthy Subjects Under Fasting Conditions
- Conditions
- Healthy
- Interventions
- Drug: ANTADYS® 100 mg, PEPCID® 20 mg
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2013-07-29
- Lead Sponsor
- Pharmaceutical Research Unit, Jordan
- Target Recruit Count
- 36
- Registration Number
- NCT01910090
- Locations
- 🇯🇴
Arab Pharmaceutical industry Consulting/ Pharmaceutical Research Unit, Amman, Jordan
The Impact of Local Analgesia for Postoperative Analgesia in Posterior Thoracolumbar Operation
- Conditions
- Pain
- Interventions
- Other: intravenousOther: local
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2014-05-02
- Lead Sponsor
- Guangzhou General Hospital of Guangzhou Military Command
- Target Recruit Count
- 71
- Registration Number
- NCT01872494
- Locations
- 🇨🇳
Guangzhou Military Region General Hospital, Department of Anesthesiology, Guangzhou, Guangdong, China
Effects of Genotype on CYP2C9 Drug Interactions
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-02-02
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 23
- Registration Number
- NCT01061112
- Locations
- 🇺🇸
Clinical and Translational Science Institute, Minneapolis, Minnesota, United States
A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis
- Conditions
- Pharyngitis
- Interventions
- First Posted Date
- 2010-01-14
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- Reckitt Benckiser LLC
- Target Recruit Count
- 198
- Registration Number
- NCT01048866
- Locations
- 🇺🇸
Bluestone Center for Clinical Research, New York, New York, United States
A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis
- First Posted Date
- 2010-01-14
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- Reckitt Benckiser LLC
- Target Recruit Count
- 204
- Registration Number
- NCT01049334
- Locations
- 🇺🇸
University of Connecticut, Student Health Services, Storrs, Connecticut, United States
The Efficacy and Safety of Flurbiprofen Chip Versus Chlorhexidine Chip (Periochip®) in Therapy of Adult Chronic Periodontitis
- First Posted Date
- 2009-12-29
- Last Posted Date
- 2010-07-07
- Lead Sponsor
- Dexcel Pharma Technologies Ltd.
- Registration Number
- NCT01040286
- Locations
- 🇮🇱
Department of Periodontology, School of Graduate Dentistry, Rambam Health Care Center, Haifa, Israel
CYP2C9 Activity Evaluated With a Simple Finger Prick
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- University Hospital, Geneva
- Target Recruit Count
- 10
- Registration Number
- NCT01026714
- Locations
- 🇨🇭
University Hospitals, Geneva 14, Switzerland
Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation
- Conditions
- Drug Interactions
- Interventions
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 87
- Registration Number
- NCT00964106
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.